Drugs for Parkinson's disease

Area of Science:

• Neurology
• Pharmacology

Background:

• Parkinson's disease (PD) management relies on pharmacotherapy and surgical interventions.
• Levodopa-carbidopa is the gold standard for PD symptom control.

Purpose of the Study:

• To review current pharmacological and non-pharmacological treatment options for Parkinson's disease.
• To outline strategies for managing motor fluctuations and complications in advanced PD.

Main Methods:

• Literature review of established and emerging therapies for Parkinson's disease.
• Analysis of drug classes including dopamine agonists, COMT inhibitors, MAO-B inhibitors, amantadine, anticholinergics, and apomorphine.
• Evaluation of deep brain stimulation as a therapeutic option.

Main Results:

• Levodopa-carbidopa provides the most effective symptomatic relief for Parkinson's disease.
• Dopamine agonists can be used as monotherapy or adjuncts to levodopa.
• Adjunctive therapies like COMT inhibitors and MAO-B inhibitors help manage motor fluctuations in advanced stages.
• Amantadine and anticholinergics offer symptomatic benefits with specific considerations for side effects.
• Subcutaneous apomorphine and deep brain stimulation are options for managing 'off' episodes and motor complications.

Conclusions:

• A multi-faceted approach combining medications and interventions is crucial for optimal Parkinson's disease management.
• Treatment selection should be individualized based on disease stage, symptoms, and patient-specific factors.
• Emerging and established therapies offer diverse strategies to improve motor control and quality of life in Parkinson's patients.